BACKGROUND: Resistant hypertension is defined as blood pressure above the target range set by current guidelines despite the concurrent use of three or more antihypertensive drugs of different classes, including a diuretic, at their maximum or highest tolerated doses. This problem affects 5% to 15% of all hypertensive patients and is thus commonly seen by both primary care physicians and specialists. METHODS: Review of current guidelines and pertinent literature revealed by a selective Medline search. RESULTS: The treatment of resistant hypertension is multimodal, involving systematic identification of secondary causes of hypertension as well as the exclusion of pseudoresistance (inadequate treatment). Non-pharmacological treatment includes weight loss, dietary salt restriction, exercise, and abstinence from alcohol. Drug treatment consists of an individualized combination of antihypertensive agents with different mechanisms of action. Activation of the sympathetic nervous system is considered to be a major element in the pathogenesis of resistant hypertension; a new interventional treatment, selective denervation of the renal sympathetic nerves, results in clinically relevant and sustained blood pressure reduction in ca. 84% of the patients undergoing the procedure (a mean decrease of office systolic blood pressure by 32 mm Hg and by 12 mm Hg at six months, p <0.001). Among the 206 patients who underwent this procedure in the setting of published studies, 5 had complications; these included pseudoaneurysm of the femoral artery and dissection of the renal artery during the introduction of the ablation catheter. CONCLUSION: The treatment of resistant hypertension is interdisciplinary and multimodal. The new and promising option of interventional renal sympathetic denervation can be considered for patients whose high blood pressure is inadequately controlled with medication.
BACKGROUND: Resistant hypertension is defined as blood pressure above the target range set by current guidelines despite the concurrent use of three or more antihypertensive drugs of different classes, including a diuretic, at their maximum or highest tolerated doses. This problem affects 5% to 15% of all hypertensivepatients and is thus commonly seen by both primary care physicians and specialists. METHODS: Review of current guidelines and pertinent literature revealed by a selective Medline search. RESULTS: The treatment of resistant hypertension is multimodal, involving systematic identification of secondary causes of hypertension as well as the exclusion of pseudoresistance (inadequate treatment). Non-pharmacological treatment includes weight loss, dietary salt restriction, exercise, and abstinence from alcohol. Drug treatment consists of an individualized combination of antihypertensive agents with different mechanisms of action. Activation of the sympathetic nervous system is considered to be a major element in the pathogenesis of resistant hypertension; a new interventional treatment, selective denervation of the renal sympathetic nerves, results in clinically relevant and sustained blood pressure reduction in ca. 84% of the patients undergoing the procedure (a mean decrease of office systolic blood pressure by 32 mm Hg and by 12 mm Hg at six months, p <0.001). Among the 206 patients who underwent this procedure in the setting of published studies, 5 had complications; these included pseudoaneurysm of the femoral artery and dissection of the renal artery during the introduction of the ablation catheter. CONCLUSION: The treatment of resistant hypertension is interdisciplinary and multimodal. The new and promising option of interventional renal sympathetic denervation can be considered for patients whose high blood pressure is inadequately controlled with medication.
Authors: David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann Journal: Hypertension Date: 2002-12 Impact factor: 10.190
Authors: Clara C Chan; Christopher M Reid; Tai-Juan Aw; Danny Liew; Steven Joseph Haas; Henry Krum Journal: J Hypertens Date: 2009-12 Impact factor: 4.844
Authors: Christian Ukena; Felix Mahfoud; Ingrid Kindermann; Christine Barth; Matthias Lenski; Michael Kindermann; Mathias C Brandt; Uta C Hoppe; Henry Krum; Murray Esler; Paul A Sobotka; Michael Böhm Journal: J Am Coll Cardiol Date: 2011-09-06 Impact factor: 24.094
Authors: Martin Thoenes; Ulrich Tebbe; Ludger Rosin; W Dieter Paar; Peter Bramlage; Wilhelm Kirch; Michael Böhm Journal: Clin Res Cardiol Date: 2011-01-05 Impact factor: 5.460
Authors: Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun Journal: Chest Date: 2007-02 Impact factor: 9.410
Authors: Jacques Amar; Bernard Chamontin; Nathalie Genes; Christelle Cantet; Michel Salvador; Jean Pierre Cambou Journal: J Hypertens Date: 2003-06 Impact factor: 4.844
Authors: David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey Journal: Circulation Date: 2008-06-24 Impact factor: 29.690
Authors: Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm Journal: Hypertension Date: 2003-11-24 Impact factor: 10.190
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Janine Pöss; Felix Mahfoud; Christian Ukena; Murray David Esler; Markus Schlaich; Dagmara Hering; Bodo Cremers; Ulrich Laufs; Michael Böhm Journal: Clin Res Cardiol Date: 2013-10-31 Impact factor: 5.460